Val66Met BDNF polymorphism as a vulnerability factor for inflammation-associated depressive symptoms in women with breast cancer

Abstract Background Inflammation contributes to the development of depression in a subset of individuals, but risk factors that render certain individuals particularly vulnerable to inflammation-associated depression are undetermined. Drawing from animal studies showing that reduced neuroplasticity...

Full description

Saved in:
Bibliographic Details
Published in:Journal of affective disorders 2016-06, Vol.197, p.43-50
Main Authors: Dooley, Larissa N, Ganz, Patricia A, Cole, Steve W, Crespi, Catherine M, Bower, Julienne E
Format: Article
Language:English
Subjects:
Adult
Aged
Alleles
BDNF
Beck Depression inventory-II
Brain-Derived Neurotrophic Factor - genetics
Breast cancer
Breast Neoplasms - genetics
Breast Neoplasms - psychology
C-Reactive Protein - analysis
CRP
Depression
Depression - blood
Depression - genetics
Depression - psychology
Female
Genetic Predisposition to Disease
Genotype
Humans
Inflammation
Inflammation - genetics
Inflammation - psychology
Middle Aged
Polymorphism, Genetic
Psychiatry
Risk Factors
Surveys and Questionnaires
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background Inflammation contributes to the development of depression in a subset of individuals, but risk factors that render certain individuals particularly vulnerable to inflammation-associated depression are undetermined. Drawing from animal studies showing that reduced neuroplasticity mediates effects of inflammation on depression, we hypothesized that individuals genetically predisposed to lower levels of neuroplasticity would be more susceptible to inflammation-associated depression. The current study examined whether the Met allele of the BDNF Val66met polymorphism, which predisposes individuals to reduced levels of brain-derived neurotrophic factor (BDNF), a protein vital for neuroplasticity, moderates the association between inflammation and depressive symptoms. Methods Our sample was 112 women with early-stage breast cancer who had recently completed cancer treatment, which can activate inflammation. Participants provided blood for genotyping and assessment of circulating inflammatory markers, and completed a questionnaire assessing depressive symptoms, including somatic, affective, and cognitive dimensions. Results There was a significant interaction between C-reactive protein (CRP) and the BDNF Val66met polymorphism in predicting cognitive depressive symptoms ( p =.004), such that higher CRP was related to more cognitive depressive symptoms among Met allele carriers, but not among Val/Val homozygotes. Post-hoc longitudinal analyses suggested that, for Met carriers, higher CRP at baseline predicted higher cognitive depressive symptoms across a one-year follow-up period ( p
ISSN:0165-0327
1573-2517
DOI:10.1016/j.jad.2016.02.059